Navigation Links
Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
Date:3/13/2008

sful transfer of manufacturing activities to Wyeth during 2007. This decrease was partially offset by increased clinical costs related to the company's Phase IIb clinical trial for TRU-015 and increased personnel-related expenses due to increased headcount.

The 12-month increase was primarily due to increased clinical costs related to the company's Phase IIb clinical trial for TRU-015, increased personnel-related expenses due to increased headcount, and increased outside manufacturing costs related to Trubion's TRU-016 product candidate. These increases were partially offset by lower outside manufacturing costs for TRU-015 due to the successful transfer of manufacturing activities to Wyeth during 2007 and lower non-cash stock-based compensation charges.

Net loss for the fourth quarter of 2007 was $4.9 million, or $0.28 per diluted common share, compared with a net loss of $4.8 million, or $0.33 per diluted common share, for the fourth quarter of 2006. For the year ended Dec. 31, 2007, net loss was $23.3 million, or $1.32 per diluted common share, compared with a net loss of $3.9 million, or $0.83 per diluted common share, for the year ended Dec. 31, 2006.

Trubion had $78.5 million in cash, cash equivalents and investments as of Dec. 31, 2007, compared with $105.8 million as of Dec. 31, 2006.

"In 2007 we continued our mission to develop a family of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy and convenience, that could offer improved patient experiences," said Peter Thompson, M.D., FACP, president, chief executive officer and chairman of Trubion. "We and our partner continued to advance the clinical development of our lead product candidate, TRU-015, for the treatment of rheumatoid arthritis, began clinical evaluation of TRU-015 in non-Hodgkin's lymphoma (NHL) and expect to do the same in systemic lupus erythematosus (SLE) later this year. In 2008, we expect our research and clinical advance
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Trubion Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Investor Conference
2. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
3. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
4. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
5. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
6. Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
7. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
8. Sagent Pharmaceuticals Launches Cefazolin for Injection, USP
9. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... PAREXEL International Corporation (NASDAQ: PRXL ), ... Partnerships in Clinical Trials named PAREXEL,s Drew Garty ... of the Year.  The honor recognizes Mr. Garty,s leadership ... MyTrials ® Data-Driven Monitoring solution. ... Partnership Awards in Boston , Mr. ...
(Date:4/23/2015)... 2015 The Thomas Brain Health ... a groundbreaking pilot study to see if early ... as little as three to six months. , ... nutritional medicine—will aggressively target and simultaneously treat the ... aging brain. These include oxidative stress, neuroinflammation, mitochondrial ...
(Date:4/23/2015)...  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced ... 2015 results before the Nasdaq market opens on Thursday, ... call and webcast to discuss its financial results and ... at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time). ... by dialing 866-952-1906 (US) or 785-424-1825 (International) using the ...
(Date:4/23/2015)... 2015  Veracyte, Inc. (NASDAQ: VCYT ) today ... to sell approximately $40 million of its common stock ... will purchase an aggregate of 4,907,975 shares of common ... the closing stock price on April 22, 2015. The ... including Broadfin Capital, Camber Capital, Deerfield, Longwood Capital Partners ...
Breaking Biology Technology:PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 2PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 3PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 4PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 5New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2015 Results 2Veracyte, Inc. Announces $40 Million Private Placement 2Veracyte, Inc. Announces $40 Million Private Placement 3Veracyte, Inc. Announces $40 Million Private Placement 4
... DIEGO, Feb. 6 SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP ) announced ... The conference information is as follows:, -- 10th Annual ... at 1:15 PM Eastern Standard Time at the Waldorf=Astoria, ... Conference: Tuesday, February 19, 2008 at 11:30 ...
... 5 BioSpecifics,Technologies Corp. (OTC Bulletin Board: BSTC) announced ... owed to it by its former CEO, Edwin H.,Wegman, ... Edwin H. Wegman,repaid the loan amount plus accrued interest ... of BioSpecifics, common stock to certain private,investors. The Estate ...
... Facility Services(R), LLC and,its family of companies ... the largest independent clinical technology maintenance and,management ... acquisition,is part of an aggressive growth strategy ... and accelerate the expansion of its,geographic footprint., ...
Cached Biology Technology:Linc Facility Services Acquires Morse Medical 2
(Date:4/13/2015)... 13, 2015 According to ... Biometrics Market Forecast & Opportunities, 2020", the global biometrics ... around 14% till 2020. The biometrics market is ... implementation and review of biometric management systems. The ... products with greater efficiency, are resulting in increasing ...
(Date:4/10/2015)... , April 10, 2015 ... addition of the "Security Competitive Profiles - NEC" ... http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to supply ... to the market, with a company focus on the ... anticipated. Winning opportunities in the ...
(Date:4/8/2015)... April 8, 2015  Infinisource, a leading provider ... and Morpho, a leading supplier of biometric identification ... the market,s most advanced biometrically-enabled time clock, the ... time clock is setting a bold, new standard ... for the small and mid-size employer. When connected ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... WEST LAFAYETTE, Ind. - Bacteria are able to build camouflaged ... by manipulating a natural cellular process. , ... a pair of proteins from the bacteria Legionella pneumophila , ... divert raw materials within the cell for use in building and ...
... from LIFE the Faculty of Life Sciences at the ... different growth pattern than non-breastfed children. Breastfeeding lowers the levels ... which means that growth is slightly slower. This is believed ... life. The PhD project is part of SKOT, ...
... camera trap video footage from the forests of Thailand ... country are paying off, according to the Wildlife Conservation ... several locations across Thailand,s Western Forest Complex over the ... the lives of tigers, Asian elephants, gaurs, sun bears, ...
Cached Biology News:Purdue scientists reveal how bacteria build homes inside healthy cells 2Purdue scientists reveal how bacteria build homes inside healthy cells 3Breastfeeding promotes healthy growth 2Candid video clips from Thailand show anti-poaching efforts saving wildlife 2
Full-length cDNA clone CS0DJ013YG01 of T cells (Jurkat cell line) of Homo sapiens (human). [Source:Uniprot/SPTREMBL;Acc:Q86SZ3] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
...
...
All-in-one mix, removes primers and dNTPs from PCR product for following direct sequencing...
Biology Products: